VISN 7 Pain Management, Opioid Safety & PDMP Program Manager U.S Department of Veterans Affairs Decatur, Georgia
This presentation offers a thorough review of the medication suzetrigine (Journavx), recently approved by the FDA for the treatment of moderate to severe acute pain. It will delve into the drug's mechanisms of action as a novel Nav1.8 inhibitor, its safety and efficacy, and its role in therapy. Additionally, future directions, including ongoing research and potential expanded indications, will be discussed
Learning Objectives:
Describe the pharmacology and novel mechanism of action of suzetrigine
Review the clinical uses, efficacy, and safety of suzetrigine based on key clinical trial data
Compare suzetrigine to existing analgesic options, emphasizing potential advantages and limitations in pain treatment
Discuss suzetrigine's place in therapy, including patient selection and potential clinical applications
Explore future directions for suzetrigine, including ongoing research and possible expanded indications for use
